Beigene

This early-stage trial tested a new drug called BGB-15025, alone or with another drug (tislelizumab), in 157 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is now complete, …

This study tested a new drug called BGB-45035 for the first time in humans. It looked at safety in healthy volunteers and then in people with autoimmune skin diseases like atopic dermatitis (eczema) and prurigo nodularis (a condition causing intensely itchy bumps). The goal was t…

This study tested whether adding an experimental drug called LBL-007 to standard immunotherapy and chemotherapy helps shrink tumors better in people with advanced esophageal cancer that cannot be surgically removed. About 118 participants received either the three-drug combo or t…

This phase 3 trial tested whether adding the immunotherapy drug tislelizumab to standard chemoradiotherapy helps people with localized esophageal squamous cell carcinoma. 370 participants received either tislelizumab or a placebo alongside chemotherapy and radiation. The study me…

This study tested combinations of three immunotherapy drugs—tislelizumab, surzebiclimab, and alcestobart—in 147 adults with advanced solid tumors that had not responded to prior treatments. The goal was to find safe doses and see if the drugs could shrink tumors. The trial is now…

This study tested the drug zanubrutinib in 65 adults with a specific genetic form (CD79B mutant) of relapsed or refractory diffuse large B-cell lymphoma, an aggressive blood cancer. Participants took zanubrutinib capsules twice daily and were monitored for tumor response and side…

This early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…

This study tested whether adding zanubrutinib to obinutuzumab works better than obinutuzumab alone for adults with follicular lymphoma that returned or didn't respond to prior treatments. About 217 people took part. The main goal was to see how many patients had their tumors shri…

This study tested the drug tislelizumab given before surgery in 33 people with early-stage colorectal cancer that has specific genetic changes (MSI-H or dMMR). The goal was to see if the drug could shrink or eliminate tumors before surgical removal. The trial has completed, and r…

This study tested giving the immunotherapy drug tislelizumab, alone or with other drugs, before surgery for people with stage II to IIIA non-small cell lung cancer that could be removed. The goal was to see if this approach could shrink tumors and improve outcomes. 121 adults too…

This study tested a drug called zanubrutinib in 96 people with certain types of B-cell lymphoma (like chronic lymphocytic leukemia or mantle cell lymphoma) who had bad side effects from similar drugs like ibrutinib or acalabrutinib. The main goal was to see if zanubrutinib causes…

This phase 2 trial tested a new drug called gimistotug (BGB-A445) combined with either another experimental drug (BGB-15025) or the standard chemo docetaxel in 35 people with advanced non-small cell lung cancer. All participants had already tried an immunotherapy and chemotherapy…

This early-phase study tested a combination of two experimental drugs (BGB-283 and PD-0325901) in 91 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drugs could shrink tumors. The trial is no…

This phase 2 trial tested whether adding the immunotherapy drug tislelizumab to chemotherapy and/or radiation before surgery could help completely eliminate esophageal cancer in 70 patients. The goal was to see if the tumor and all cancer cells in lymph nodes were gone at the tim…

This study tested a drug called zanubrutinib in 55 Japanese patients with B-cell blood cancers that had come back or not responded to prior treatment. The goal was to check safety and how well the drug works. Zanubrutinib is taken as a pill twice daily and targets a protein that …

This Phase 3 study tested a new immunotherapy drug, tislelizumab, against the standard targeted therapy sorafenib in 684 adults with advanced liver cancer that could not be removed by surgery. Participants received either tislelizumab intravenously every three weeks or sorafenib …

This early-phase study tested a combination of two immunotherapy drugs, BGB-A445 and tislelizumab, in 204 people with advanced solid tumors including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. The trial is now comp…

This Phase 2 trial tested the drug tislelizumab in 46 people with classical Hodgkin lymphoma that had come back or was not responding to treatment. The main goal was to see how many participants had their tumors shrink or disappear. Participants received the drug every 3 weeks un…

This study tested whether adding an experimental immunotherapy drug (ociperlimab) to a standard immunotherapy (tislelizumab) plus chemotherapy could help people with advanced non-small cell lung cancer. The trial involved 272 patients whose cancer had spread or could not be remov…

This early-phase trial tested a new drug called ociperlimab combined with either tislelizumab or rituximab in 53 people whose diffuse large B-cell lymphoma had returned or stopped responding to treatment. The main goal was to check safety and find the right dose. Researchers also…

This early-stage trial tested an experimental oral drug called BGB-16673 in 34 adults with chronic spontaneous urticaria (CSU), a condition causing persistent hives and itching. The study was double-blind and placebo-controlled, meaning neither patients nor doctors knew who got t…

This study looked at how two common drugs (phenytoin and itraconazole) change the way the body handles BGB-16673. It involved 37 healthy adults aged 18-65. The goal was to measure drug levels in the blood, not to treat any disease.

This early-phase trial tested the safety and tolerability of an experimental drug called BGB-23339 in 92 healthy adults. Participants received either the drug or a placebo as an oral tablet. The main goal was to see how the body handles the drug and whether it causes any side eff…

This completed Phase 1 study looked at how two different tablet forms of the drug BGB-43395 are absorbed in 51 healthy adults aged 18-65. It also checked whether taking the drug with food changes absorption. The goal was to gather basic information, not to treat any disease.